MCK vs. COR, CAH, BDX, ZTS, HCA, GILD, BMY, EW, DXCM, and MRNA
Should you be buying McKesson stock or one of its competitors? The main competitors of McKesson include Cencora (COR), Cardinal Health (CAH), Becton, Dickinson and Company (BDX), Zoetis (ZTS), HCA Healthcare (HCA), Gilead Sciences (GILD), Bristol-Myers Squibb (BMY), Edwards Lifesciences (EW), DexCom (DXCM), and Moderna (MRNA). These companies are all part of the "medical" sector.
McKesson (NYSE:MCK) and Cencora (NYSE:COR) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability, community ranking and valuation.
McKesson has higher revenue and earnings than Cencora. Cencora is trading at a lower price-to-earnings ratio than McKesson, indicating that it is currently the more affordable of the two stocks.
McKesson has a net margin of 0.97% compared to Cencora's net margin of 0.67%. Cencora's return on equity of 268.67% beat McKesson's return on equity.
In the previous week, McKesson had 18 more articles in the media than Cencora. MarketBeat recorded 20 mentions for McKesson and 2 mentions for Cencora. McKesson's average media sentiment score of 0.57 beat Cencora's score of 0.50 indicating that McKesson is being referred to more favorably in the media.
McKesson has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Cencora has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.
McKesson received 214 more outperform votes than Cencora when rated by MarketBeat users. Likewise, 74.16% of users gave McKesson an outperform vote while only 65.12% of users gave Cencora an outperform vote.
McKesson currently has a consensus price target of $571.47, indicating a potential upside of 1.23%. Cencora has a consensus price target of $233.90, indicating a potential upside of 5.30%. Given Cencora's higher possible upside, analysts clearly believe Cencora is more favorable than McKesson.
85.1% of McKesson shares are owned by institutional investors. Comparatively, 97.5% of Cencora shares are owned by institutional investors. 0.2% of McKesson shares are owned by insiders. Comparatively, 15.8% of Cencora shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
McKesson pays an annual dividend of $2.48 per share and has a dividend yield of 0.4%. Cencora pays an annual dividend of $2.04 per share and has a dividend yield of 0.9%. McKesson pays out 11.1% of its earnings in the form of a dividend. Cencora pays out 22.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Summary
McKesson beats Cencora on 14 of the 20 factors compared between the two stocks.
Get McKesson News Delivered to You Automatically
Sign up to receive the latest news and ratings for MCK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MCK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
McKesson Competitors List
Related Companies and Tools
